PaPE-1
SIGMA/SML1876 - ≥98% (HPLC)
Synonym: (S)
CAS Number: 2107327-36-4
Empirical Formula (Hill Notation): C17H18O2
Molecular Weight: 254.32
MDL Number: MFCD30723184
Linear Formula: C17H18O2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C17H18O2/c1-10-7-14(8- |
| InChI key | UCXWFKNKSWDWCD-INIZCTEOSA |
| Quality Level | 100  |
| SMILES string | O[C@H]1CCC2=C1C=CC(C3=CC( |
| solubility | DMSO: 25 mg/mL, clear |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | PaPE-1 is a "Pathway Preferential Estrogen" that activates the extranuclear signaling pathway without activating the nuclear signaling pathway. |
| Biochem/physiol Actions: | PaPE-1 is a "Pathway Preferential Estrogen" that activates the extranuclear signaling pathway without activating the nuclear signaling pathway. PaPE-1 bound 50,000-fold less well to ERα and Erβ estrogen receptors. PaPE-1 activated extranuclear-initiated ER-regulated genes, but showed essentially no activation of nuclear-initiated estrogen receptor (ER) gene targets such as the progesterone receptor. Unlike estradiol (E2), PaPE-1 did not stimulate proliferation of MCF-7 breast cancer cells. Like estradiol, PaPE-1 strongly activated MAPK and mTOR pathway. Instead, it showed preferential estrogen-like activity in non-reproductive (metabolic and vascular) tissues, reducing body weight gain and fat accumulation in ovariectomized mice and accelerating repair of endothelial damage in the vascualture. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 |
| Precautionary statements | P305 + P351 + P338 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 51111800 |